Evidence map›Paper›PMID 37762894›Full record

ArticleJournal of clinical medicine2023

Sodium Valproate Use in Japanese Patients with Schizophrenia and Coronavirus Disease Is Associated with an Increased Risk of Pneumonia.

Yusuke Arai, Daimei Sasayama, Akira Kuraishi, Reiko Sahara, Shiho Murata, Akira Tanaka, Kotaro Amemiya, Nobuteru Usuda, Kazuaki Kuraishi, Shinsuke Washizuka

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yusuke AraiDepartment of Psychiatry, Shinshu University School of Medicine, Matsumoto-City 390-8621, Japan.ORCID 0000-0002-3155-6971
Daimei SasayamaDepartment of Psychiatry, Shinshu University School of Medicine, Matsumoto-City 390-8621, Japan.ORCID 0000-0003-3450-7283
Akira KuraishiDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Reiko SaharaDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Shiho MurataDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Akira TanakaDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Kotaro AmemiyaDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Nobuteru UsudaDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Kazuaki KuraishiDepartment of Psychiatry, Kurita Hospital, Nagano-City 380-0921, Japan.
Shinsuke WashizukaDepartment of Psychiatry, Shinshu University School of Medicine, Matsumoto-City 390-8621, Japan.
Shinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is a known risk factor for coronavirus disease (COVID-19) infection and severity, and certain psychotropic drugs have been linked to increased mortality in infected patients with schizophrenia. However, little evidence exists regarding this risk. We retrospectively examined the association between mood stabilizers and the risk of pneumonia in patients with schizophrenia. This study included 99 patients with schizophrenia or schizoaffective disorder who were infected with COVID-19 in 2022 and met the inclusion criteria. After conducting propensity score matching to align patient backgrounds and concomitant medications, we assessed the impact of mood stabilizers, specifically sodium valproate, on the risk of pneumonia development. Univariate analysis revealed that patients with schizophrenia and COVID-19 who developed pneumonia were more likely to be older (64.5 [14.2] vs. 57.4 [11.5] years,

Indexed as

COVID-19mood stabilizerpneumoniaschizophreniasodium valproate

Identifiers

PMID37762894
PMCPMC10532378
OpenAlexW4386743969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.